Jorgeth de Oliveira Carneiro da Motta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jorgeth de Oliveira Carneiro da Motta has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ciro Martins Gomes
Universidade de Brasília, Brasil
4 shared publications - Patrícia Shu Kurizky
Medical Sciences, School of Medicine, University of Brasília, Brasília, DF, Brazil
3 shared publications - Camila Bocchi Siqueira
Department of Dermatology, Hospital Universitário de Brasília, Brasilia, DF, Brazil
2 shared publications - Cláudia Porto
Department of Dermatology, Hospital Regional da Asa Norte, Brasília, DF, Brazil
2 shared publications - Felipe von Glehn
Faculty of Medicine, University of Brasília (UNB), Brasília 70910-900, Brazil
2 shared publications - Ingrid Faber de Vasconcellos
Department of Neurology University of Brasília Brasília DF Brazil
2 shared publications
Latest Publications
- Open Access
- 1 September 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (5) , 736-739
Uso de imunoglobulina intravenosa como terapia de resgaste da neurite parainfecciosa hansênica refratária: série de casos
- 1 September 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (5) , 736-739
Open AccessUso de imunoglobulina intravenosa como terapia de resgaste da neurite parainfecciosa hansênica refratária: série de casos
- Open Access
- 3 June 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (5) , 736-739
The use of intravenous immunoglobulin as a rescue therapy for refractory parainfectious leprosy-related neuritis: a case series
- 3 June 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (5) , 736-739
Open AccessThe use of intravenous immunoglobulin as a rescue therapy for refractory parainfectious leprosy-related neuritis: a case series
- Open Access
- 15 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (5) , 602-604
Successful treatment of diffuse cutaneous leishmaniasis caused by Leishmania amazonensis
- 15 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (5) , 602-604
Open AccessSuccessful treatment of diffuse cutaneous leishmaniasis caused by Leishmania amazonensis
- Open Access
- 1 July 2021
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11
A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
Introduction: American tegumentary leishmaniasis (ATL), which can present as either cutaneous (CL) or mucosal leishmaniasis (ML), is endemic in South America, and first-line antimonial treatments are known for their wide range of adverse effects (AEs). Growing reports of drug resistance increase the urgency of the need for better treatment options. The objective of this pilot clinical trial was to assess the efficacy of and AEs associated with the oral combination of miltefosine and pentoxifylline based on a post hoc analysis.Methods: A pilot, randomized, open-label clinical trial was performed. The experimental group (M+P) received 50 mg twice a day (BID) miltefosine and 400 mg three times a day (TID) pentoxifylline, and the control group (A+P) received 20 mg Sb+V/kg/day intravenously and 400 mg TID pentoxifylline. Patients with ML received treatment for 28 days, and patients with CL received treatment for 20 days.Results: Forty-three patients were included: 25 with ML and 18 with CL caused by L.(V.) braziliensis. AEs were more frequent in the A+P group (p=0.322), and there was a need for treatment interruption due to severe AEs (p=0.027). Patients with CL had a higher chance of achieving a cure (p=0.042) and a higher risk of AEs (p=0.033). There was no difference in the chance of a cure based on the treatment (p=0.058).Conclusion: In this pilot randomized clinical trial, M+P treatment and A+P treatment yielded similar cure rates, and the former was associated with a lower risk of AEs. Future studies with more patients and longer follow-up are recommended.
- 1 July 2021
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11
Open AccessA Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
Introduction: American tegumentary leishmaniasis (ATL), which can present as either cutaneous (CL) or mucosal leishmaniasis (ML), is endemic in South America, and first-line antimonial treatments are known for their wide range of adverse effects (AEs). Growing reports of drug resistance increase the urgency of the need for better treatment options. The objective of this pilot clinical trial was to assess the efficacy of and AEs associated with the oral combination of miltefosine and pentoxifylline based on a post hoc analysis.Methods: A pilot, randomized, open-label clinical trial was performed. The experimental group (M+P) received 50 mg twice a day (BID) miltefosine and 400 mg three times a day (TID) pentoxifylline, and the control group (A+P) received 20 mg Sb+V/kg/day intravenously and 400 mg TID pentoxifylline. Patients with ML received treatment for 28 days, and patients with CL received treatment for 20 days.Results: Forty-three patients were included: 25 with ML and 18 with CL caused by L.(V.) braziliensis. AEs were more frequent in the A+P group (p=0.322), and there was a need for treatment interruption due to severe AEs (p=0.027). Patients with CL had a higher chance of achieving a cure (p=0.042) and a higher risk of AEs (p=0.033). There was no difference in the chance of a cure based on the treatment (p=0.058).Conclusion: In this pilot randomized clinical trial, M+P treatment and A+P treatment yielded similar cure rates, and the former was associated with a lower risk of AEs. Future studies with more patients and longer follow-up are recommended.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54, e03362021
Dramatic secukinumab-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways
A 39-year-old woman was diagnosed with relapsed multibacillary leprosy and refractory neuritis. Here, we describe an evident loss of therapeutic effectiveness after the third pulse of corticosteroids, which may be attributed to tachyphylaxis and the posterior modulation of interferon- γ (IFN-γ), tumor necrosis factor- α (TNF-α,) interleukin-17A (IL-17A), and IL-12/23p40 after the induction phase of secukinumab. In this case, plasma cytokine analysis showed that secukinumab induced a reduction in IL-17 concomitant with impressive clinical improvements in the patient’s neural function. Interestingly, secukinumab induced reductions in cytokines related to Th1 responses and earlier stages of the Th17 response, including IL-23/12.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54, e03362021
Open AccessDramatic secukinumab-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways
A 39-year-old woman was diagnosed with relapsed multibacillary leprosy and refractory neuritis. Here, we describe an evident loss of therapeutic effectiveness after the third pulse of corticosteroids, which may be attributed to tachyphylaxis and the posterior modulation of interferon- γ (IFN-γ), tumor necrosis factor- α (TNF-α,) interleukin-17A (IL-17A), and IL-12/23p40 after the induction phase of secukinumab. In this case, plasma cytokine analysis showed that secukinumab induced a reduction in IL-17 concomitant with impressive clinical improvements in the patient’s neural function. Interestingly, secukinumab induced reductions in cytokines related to Th1 responses and earlier stages of the Th17 response, including IL-23/12.